Enanta Pharma (ENTA) Tops Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015
November 23, 2015 4:01 PM ESTConference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue of $14.4 million in fourth quarter brings fiscal year total to $34.1 million AbbVies phase 3 trial begun for next-generation HCV treatment containing Enantas protease inhibitor ABT-493 Enantas cyclophilin inhibitor candidate EDP-494 expected to enter the clinic in the first calendar quarter of 2016 Cash and marketable securities totaled $209 million at September 30, 2015WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ:... More
